May 20, 2022

The Japan Herald

About Japan, Global Green Energy and Space Market

Cutaneous Leishmaniasis Drugs Market – Global Outlook and Forecast 2022-2028

4 min read

Cutaneous leishmaniasis is the most common syndrome and can produce ulcers that have the potential of stimulating a periosteal reaction if the ulcer occurs near bone.

Leishmaniasis, a protozoal infection transmitted by sandfly bite, produces a clinical spectrum of disease ranging from asymptomatic infection to ulcerative skin and mucosal lesions to visceral involvement. Leishmaniasis is endemic in regions of Africa, the Middle East, south Asia, southern Europe, northern South America, and Central America. There has been an increase in imported leishmaniasis into developed, non-endemic countries due to increasing global travel. While pentavalent antimonials have been the mainstay of antileishmanial treatment for decades, newer therapeutic options have become available for all forms of infection, including liposomal amphotericin B, miltefosine, fluconazole, and ketoconazole.

This report contains market size and forecasts of Cutaneous Leishmaniasis Drugs in global, including the following market information:

Global Cutaneous Leishmaniasis Drugs Market Revenue, 2017-2022, 2023-2028, ($ millions)

 

Global Cutaneous Leishmaniasis Drugs Market Sales, 2017-2022, 2023-2028, (K Units)

Global top five Cutaneous Leishmaniasis Drugs companies in 2021 (%)

The global Cutaneous Leishmaniasis Drugs market was valued at 44 million in 2021 and is projected to reach US$ 58 million by 2028, at a CAGR of 3.9% during the forecast period.

The U.S. Market is Estimated at $ Million in 2021, While China is Forecast to Reach $ Million by 2028.

Pentavalent Antimonials Segment to Reach $ Million by 2028, with a % CAGR in next six years.

The global key manufacturers of Cutaneous Leishmaniasis Drugs include GSK, Novartis, Sanofi, Gilead Sciences, Bristol-Myers Squibb, Albert David, Profounda, Knight Therapeutics and Pfizer and etc. In 2021, the global top five players have a share approximately % in terms of revenue.

We surveyed the Cutaneous Leishmaniasis Drugs manufacturers, suppliers, distributors and industry experts on this industry, involving the sales, revenue, demand, price change, product type, recent development and plan, industry trends, drivers, challenges, obstacles, and potential risks.

Total Market by Segment:

Global Cutaneous Leishmaniasis Drugs Market, by Type, 2017-2022, 2023-2028 ($ Millions) & (K Units)

Global Cutaneous Leishmaniasis Drugs Market Segment Percentages, by Type, 2021 (%)

  • Pentavalent Antimonials
  • Antifungal Drugs

Anti-Leishmanial/Antimicrobial Drugs

Global Cutaneous Leishmaniasis Drugs Market, by Application, 2017-2022, 2023-2028 ($ Millions) & (K Units)

Global Cutaneous Leishmaniasis Drugs Market Segment Percentages, by Application, 2021 (%)

  • Hospital
  • Retail Pharmacy
  • Others

Global Cutaneous Leishmaniasis Drugs Market, By Region and Country, 2017-2022, 2023-2028 ($ Millions) & (K Units)

Global Cutaneous Leishmaniasis Drugs Market Segment Percentages, By Region and Country, 2021 (%)

  • North America
  • US
  • Canada
  • Mexico
  • Europe
  • Germany
  • France
  • U.K.
  • Italy
  • Russia
  • Nordic Countries
  • Benelux
  • Rest of Europe
  • Asia
  • China
  • Japan
  • South Korea
  • Southeast Asia
  • India
  • Rest of Asia
  • South America
  • Brazil
  • Argentina
  • Rest of South America
  • Middle East & Africa
  • Turkey
  • Israel
  • Saudi Arabia
  • UAE
  • Rest of Middle East & Africa

Competitor Analysis

The report also provides analysis of leading market participants including:

  • Key companies Cutaneous Leishmaniasis Drugs revenues in global market, 2017-2022 (Estimated), ($ millions)
  • Key companies Cutaneous Leishmaniasis Drugs revenues share in global market, 2021 (%)
  • Key companies Cutaneous Leishmaniasis Drugs sales in global market, 2017-2022 (Estimated), (K Units)
  • Key companies Cutaneous Leishmaniasis Drugs sales share in global market, 2021 (%)

Further, the report presents profiles of competitors in the market, key players include:

  • GSK
  • Novartis
  • Sanofi
  • Gilead Sciences
  • Bristol-Myers Squibb
  • Albert David
  • Profounda
  • Knight Therapeutics
  • Pfizer
  • Xinhua Pharma

Table of content

1 Introduction to Research & Analysis Reports
1.1 Cutaneous Leishmaniasis Drugs Market Definition
1.2 Market Segments
1.2.1 Market by Type
1.2.2 Market by Application
1.3 Global Cutaneous Leishmaniasis Drugs Market Overview
1.4 Features & Benefits of This Report
1.5 Methodology & Sources of Information
1.5.1 Research Methodology
1.5.2 Research Process
1.5.3 Base Year
1.5.4 Report Assumptions & Caveats
2 Global Cutaneous Leishmaniasis Drugs Overall Market Size
2.1 Global Cutaneous Leishmaniasis Drugs Market Size: 2021 VS 2028
2.2 Global Cutaneous Leishmaniasis Drugs Revenue, Prospects & Forecasts: 2017-2028
2.3 Global Cutaneous Leishmaniasis Drugs Sales: 2017-2028
3 Company Landscape
3.1 Top Cutaneous Leishmaniasis Drugs Players in Global Market
3.2 Top Global Cutaneous Leishmaniasis Drugs Companies Ranked by Revenue
3.3 Global Cutaneous Leishmaniasis Drugs Revenue by Companies
3.4 Global Cutaneous Leishmaniasis Drugs Sales by Companies
3.5 Global Cutaneous Leishmaniasis Drugs Price by Manufacturer (2017-2022)
3.6 Top 3 and Top 5 Cutaneous Leishmaniasis Drugs Companies in Global Market, by Revenue in 2021
3.7 Global Manufacturers Cutaneous Leishmaniasis Drugs Product Type
3.8 Tier 1, Tier 2 and Tier 3 Cutaneous Leishmaniasis Drugs Players in Global Market
3.8.1 List of Global Tier 1 Cutaneous Leishmaniasis Drugs Companies
3.8

CONTACT US:
276 5th Avenue, New York, NY 10001, United States
International: +1(646)-781-7170 / +91 8087042414

Similar Reports:

Global Cutaneous Leishmaniasis Drugs Market Insights and Forecast to 2028

Global Cutaneous Leishmaniasis Drugs Market Research Report 2022 Professional Edition

Global Cutaneous Leishmaniasis Drugs Market Outlook 2022

Global and Regional Cutaneous Leishmaniasis Drugs Industry Status and Prospects Professional Market Research Report Standard Version 2021-2027

Leave a Reply

Your email address will not be published. Required fields are marked *